Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 1045-1051

  Björck, Lena ^a   Welin, Catharina ^b   Rosengren, Annika ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Lipid levels; Lipid lowering medication; Myocardial infarction; Risk factors

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INFORMATION PROCESSING; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; SEX DIFFERENCE; TREND STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SEX FACTORS; SWEDEN; TRIGLYCERIDES;

EID: 38149064384     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Anonymous. 1975. Clofibrate and macin in coronary heart disease. JAMA, 231:360-81.
2. Anonymous. 1980. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet, 2:379-85.
3. Anonymous. 1984a. The Lipid Research Clinics Coronary Primary Prevention Trial results. Reduction in incidence of coronary heart disease. JAMA, 251:351-64.
4. Anonymous. 1984b. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA, 251:365-74.
5. Anonymous. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sirnvastatin Survival Study (4S). Lancet, 344:1383-9.
6. Anonymous. 2001. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J, 22:554-72.
7. Abildstrom SZ, Rasmussen S, Rosen M, et al. 2003. Trends in incidence and case fatality rates of acute myocardial infarction in Denmark and Sweden. Heart, 89:507-11.
8. Becker W, Pearson M. 2002. Riksmaten 1997-98, kostvanor och n⊣sringsintag i Sverige, metod-och resultatrapport (Dierary habits and nutrient intake in Sweden 1997-98). Uppsala, Information and Nutrition Department, Swedish National Food Administration.
9. Berg CM, Lissner L, Aires N, et al. 2005. Trends in blood lipid levels, blood pressure, alcohol and smoking habits from 1985 to 2002: results from INTERGENE and GOT-MONICA. Eur J Cardiovasc Prev Rehab, 12:115-25.
10. Blankenhorn DH, Nessim SA, Johnson RL, et al. 1987. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA, 257:3233-40.
11. Brensike JF, Levy RI, Kelsey SF, et al. 1984. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation, 69:313-24.
12. Buchwald H, Varco RL, Matts JP, et al. 1990. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidernias (POSCH). N Engl J Med, 323:946-55.
13. De Backer G, Ambrosioni E, Borch-Johnsen, et al. 2003. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J, 24:1601-10.
14. Evans A, Tolonen H, Hense HW, et al. 2001. Trends in coronary risk factors in the WHO MONICA project. Int J Epidemiol, 30 (Suppl 1):35-40.
15. [HPSCG] Heart Protection Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with siravastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360:7-22.
16. Law MR, Wald NJ. 1994. An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr, 48:305-25. Law MR, Wald NJ, Thompson SG. 1994a. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ, 308:367-72.
17. Law MR, Wald NJ, Wu T, et al. 1994b, Systematic underestimation of association between senun cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ, 308:363-6.
18. Levy RI, Brensike, JF, Epstein SE, et al. 1984. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation, 69:325-37.
19. Pekkanen J, Linn S, Heiss G, et al. 1990. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med, 322:1700-7.
20. Sharrett AR, Ballantyne, CM, Coady SA, et al. 2001. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteiris A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 104:1108-13.
21. Shekelle RB, Shyrock AM, Paul O, et al. 1981. Diet, serum cholesterol, and death from coronary heart disease. The Western Electric study. N Engl J Med, 304:65-70.
22. Watts GF, Lewis B, Brunt, JN, Lewis, ES, et al. 1992. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet, 339:563-9.
23. Wilhelmsen L, Johansson S, Rosengren A, et al. 1997. Risk factors for cardiovascular disease during the period 1985-1995 in Goteborg, Sweden. The GOT-MONICA Project. J Intern Med, 242:199-211.